Workflow
科华生物(002022) - 2023 Q3 - 季度财报
KHBKHB(SZ:002022)2023-10-27 16:00

Financial Performance - The company's revenue for Q3 2023 was ¥507,746,754.42, a decrease of 65.44% compared to the same period last year[5] - The net profit attributable to shareholders was -¥41,082,204.59, representing a decline of 122.01% year-on-year[5] - The basic earnings per share for the period was -¥0.0799, down 122.01% from the previous year[5] - Total operating revenue for the current period is CNY 1,904,222,528.93, a decrease from CNY 5,382,824,487.50 in the previous period, representing a decline of approximately 64.7%[17] - Net profit for the current period is CNY 48,569,569.90, a significant decrease from CNY 1,932,027,220.32 in the previous period, reflecting a decline of approximately 97.5%[19] - The company recorded a total comprehensive income of CNY 64,458,740.25, down from CNY 1,928,649,778.58 in the previous period, reflecting a decrease of approximately 96.7%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,038,165,189.77, a decrease of 20.14% from the end of the previous year[5] - Total current assets amount to ¥4,571,937,062.51, a decrease from ¥6,445,298,850.16 at the beginning of the year[14] - Total non-current assets are reported at ¥2,466,228,127.26, compared to ¥2,367,858,163.16 at the start of the year[15] - Total current liabilities are ¥878,252,349.76, significantly lower than ¥2,053,128,583.43 at the beginning of the year[15] - Total liabilities stand at ¥1,813,253,376.66, compared to ¥2,961,151,839.11 previously[15] - The company has a total equity of ¥5,224,911,813.11 as of September 30, 2023[15] Cash Flow - Cash flow from operating activities showed a net outflow of -¥543,354,193.70, an increase in expenditure of 136.87% year-on-year[5] - The company reported a net cash flow from operating activities of CNY -543,354,193.70, compared to CNY 1,473,832,871.47 in the previous period, indicating a negative shift in cash flow[20] - The cash inflow from operating activities totaled CNY 2,110,280,610.29, a decrease from CNY 5,579,674,352.29 in the previous period, indicating a decline of about 62.2%[20] - In Q3 2023, the net cash flow from investment activities was -581,634,752.95 CNY, compared to -229,736,010.09 CNY in Q3 2022, indicating a significant increase in cash outflow[21] - The total cash outflow from financing activities reached 695,804,612.47 CNY in Q3 2023, up from 156,988,822.21 CNY in the same period last year, reflecting increased financial obligations[21] - The net cash flow from financing activities was -519,092,154.67 CNY in Q3 2023, contrasting with a positive cash flow of 45,404,973.78 CNY in Q3 2022, highlighting a shift in financing dynamics[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 49,939[11] - The largest shareholder, Zhuhai Baolian Investment, holds 18.64% of shares, totaling 95,863,038 shares, with 24,000,000 shares pledged[11] Expenses and Investments - Research and development expenses increased to CNY 186,166,801.41 from CNY 157,608,564.43, marking an increase of about 18.1%[17] - The company invested 184,000,000.00 CNY in capital expenditures during Q3 2023, indicating ongoing investment in fixed and intangible assets[21] - The company reported a significant increase in cash paid for dividends and interest, totaling 527,298,117.29 CNY in Q3 2023, compared to 69,290,664.65 CNY in Q3 2022[21] Accounting and Audit - The company has not undergone an audit for the Q3 2023 report, which may affect the perception of financial reliability[22] - The company is implementing new accounting standards starting in 2023, which may impact future financial reporting and analysis[22]